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Available online ▪ ▪ ▪AbstractPurpose: To review current literature on the renin-angiotensin system (RAS)-mediated pathogenic mechanisms and therapeutic targets in ocular
diseases.
Methods: A comprehensive literature survey was performed on PubMed, Scopus, and Google Scholar database published from 1977 to 2016.
The search terms were a renin-angiotensin system, angiotensin, angiotensin receptor, prorenin, pro (renin) receptor, angiotensin converting
enzyme inhibitor, angiotensin receptor blocker associated with ocular disorders like cataract, glaucoma, diabetic retinopathy, macular degen-
eration, and uveitis. Articles were reviewed on the basis of the association between ocular disorders and RAS and relevant articles were
discussed.
Results: The literature revealed that the individual RAS components including renin, angiotensins, angiotensin converting enzymes, and RAS
receptors have been expressed in the specific ocular tissues like retina, choroid, and ciliary body. The activation of both circulatory and local
RAS potentiate the various inflammatory and angiogenic signaling molecules, including vascular endothelial growth factor, extracellular signal-
regulated kinase, and advanced glycation end products in the ocular tissues and leads to several blinding disorders like diabetic retinopathy,
glaucoma, and macular degeneration. The classical and newer RAS inhibitors have illustrated protective effects on blinding disorders, including
diabetic retinopathy, glaucoma, macular degeneration, uveitis, and cataract.
Conclusions: The RAS components are present in the extrarenal tissues including ocular tissue and have an imperative role in the ocular
pathophysiology. The clinical studies are needed to show the role of therapeutic modalities targeting RAS in the treatment of different ocular
disorders.
Copyright © 2016, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction converted to octapeptide angiotensin II (Ang-II) by theThe circulatory renin-angiotensin system (RAS) plays an
important role in the regulation of blood pressure, fluid vol-
ume, electrolyte balance, and inflammation.1 The circulatory
RAS system initiates with renin which cleaves angiotensi-
nogen to form the decapeptide angiotensin I (Ang-I) is thenFunding information: None.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).angiotensin-converting enzyme (ACE).2 Ang-II regulates
various biological effects through the activation of Angio-
tensin II type I receptors (AT1R) and Angiotensin II type 2
receptors (AT2R). Ang-II elicits most of its well-known bio-
logical effects, including vasoconstriction, electrolyte ho-
meostasis, fibrosis, inflammation, and proliferation through
activation of AT1R.
3e5 The actions of the AT2R are not so
much defined, but they possibly oppose the actions of the
AT1R like vasodilatory effects.
6 However, findings indicate
that AT2R acts similar to AT1R, like promoting cell growth,
apoptosis, and angiogenesis in some tissues.7e9
Plethora researchers highlighted the significance of the
local RAS in various extrarenal tissues, including the adrenalin-angiotensin system in ocular disorders, Journal of Current Ophthalmology
sting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
2 R. Choudhary et al. / Journal of Current Ophthalmology xx (2016) 1e10
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functional role of the RAS components, including prorenin,
renin, ACE, angiotensinogen, Ang-II, (pro)renin receptor ((P)
RR), and AT1R in the eye have been established in the several
species (Table 1). These findings propose that the local RAS
plays an important role in the regulation of the ocular physi-
ology. The aim of our present article is to review the role of the
RAS in the regulation of various ocular disorders such as
diabetic retinopathy (DR), glaucoma, age-related macular
degeneration (AMD), uveitis, and cataract, and beneficial ef-
fects of RAS regulation through RAS inhibitors in the thera-
peutic management of such ocular disorders.
Methods
This narrative review was based on a literature search using
PubMed, Scopus, and Google Scholar databases from 1977 toTable 1
Distribution of RAS components in ocular tissues in different species.
RAS components Localization
Prorenin Retina, vitreous fluids, iris, ciliary body,
choroid, sclera, cornea, conjunctiva
Renin Retina (Muller cells, RPE), iris, vitreous fluid, choro
Ciliary body
Sclera, cornea
Aqueous fluid
Angiotensinogen Retina (Muller cells, RPE), ciliary body,
vitreous fluid, choroid, iris
Sclera, cornea, conjunctiva
Aqueous fluid
Ang-I Retina, choroid, subretinal fluid
Aqueous fluid
Vitreous fluid
Ang-II Retina (Muller cells, retinal vessel
endothelial cells, ganglion cells, photoreceptor cells,
subretinal fluid), vitreous fluid, choroid
Ciliary body, aqueous fluid
Cornea
Iris
Ang (1e7) Retinal Muller cells, aqueous humor
ACE Retina (Muller cells, ganglion cells, retinal vessel
endothelial cells, photoreceptor cells), choroid
Ciliary body
Aqueous fluid
Vitreous fluid
Tear fluid
Cornea, conjunctiva
Iris
Sclera
ACE2 Retina
Chymase Vitreous fluid
(P)RR Retina (Muller cells, RPE, ganglion cells),
choroid, iris, ciliary body, cornea, conjunctiva
AT1R Retina (Muller cells, amacrine cells, RPE, blood vess
photoreceptors, ganglion cells), choroid, cornea,
ciliary body, iris, conjunctiva
AT2R Retina (Muller cells, nuclei of some inner nuclear
layer neurons, and ganglion cell nuclei)
Mas receptor Retina, ciliary body
ACE: angiotensin-converting enzyme; ACE2: angiotensin-converting enzyme type
AT1R: angiotensin II type 1 receptor; AT2R: angiotensin II type 2 receptor; (P)RR
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angiotensin, angiotensin receptor, prorenin, pro (renin) re-
ceptor, angiotensin converting enzyme inhibitor, angiotensin
receptor blocker associated with ocular disorders like cataract,
glaucoma, diabetic retinopathy, macular degeneration, and
uveitis. All article types, including original research article,
reviews, and case reports that described the role of RAS in
ocular disorders were selected and reviewed thoroughly by the
authors to review RAS-mediated pathogenic mechanisms and
therapeutic targets in ocular diseases.
Results
During the literature survey, 180 articles were retrieved
from the databases. 148 articles were found relevant to the
discussion in the present review. After extensively examining
the plethora of literature on the various aspects of ocular RAS,Species References
Human 2,14,15,17
id Human, rabbit 2,14,18e22
Human, rabbit, rat
Human
Rabbit
Human, rabbit 2,21,22
Human
Rabbit
Porcin 14,16
Human
Human, porcine
Human, rabbit, porcine 16,21,23e25
Human, rabbit
Human
Rabbit
Human 25,26
Human, monkey, dog, rabbit, porcine 2,21,22,24,26e40
Human, rabbit, rat, porcine
Human, monkey, dog, rabbit
Monkey, dog, rabbit
Human, rabbit
Human
Human, rabbit, porcine
Human, monkey, dog
Human, rodent, porcine 25,26,41,42
Human 33
Human 2,43,44,132
els, Human 2,20,24,25,45e48
Human 9,25
Human, Rabbit, rats 49e51
2; Ang (1e7): angiotensin (1e7); Ang-I: angiotensin I; Ang-II: angiotensin II;
: (pro)renin receptor; RAS: renin-angiotensin system.
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ocular disorders, we reviewed the essentiality of the ocular
RAS system along with its role in ocular disorders.Expression of RAS components in the eyeOcular RAS has been the focus of growing interest in the
recent year after finding the RAS components in the ocular
tissues. The literature concerning that research on the ocular
RAS started with a study by Igic and coworkers on the
detection of ACE activity in retinal homogenates.13 There-
after, RAS components in the eye have been established in
various research studies (Table 1).
In early studies, RAS components were found in the eye but
there was a lake to identify the origin of the ocular RAS, either
local production or selective uptake by ocular tissues from the
circulatory RAS.13e15 This question has been refused after
findings of Danser et al that the circulatory RAS components,
including angiotensinogen, Ang-I, and Ang-II from plasma
could not enter into the eye,16 suggesting that RAS compo-
nents in the ocular tissues are locally synthesized, which is
affirmed by Brandt et al after finding the renin mRNA in the
eye.19 These findings suggest that the presence of RAS com-
ponents in ocular tissues play a pivotal role in the ocular
pathophysiology.Ocular RAS signaling cascades
Angiotensin II-dependent signaling cascades
On the basis of literature, RAS signaling cascades in the
eye are represented in Fig. 1. The circulatory RAS components
are unable to enter into ocular cells,16 but Milenkovic
et al found that systemic infusion of Ang-II into mice de-
creases renin expression in the kidney and reduces the renin
mRNA levels in both retinal pigment epithelium (RPE) cells
and neuronal retina, whereas systemic application of ACE
inhibitors (ACEIs) increased renin expression in RPE by 20-
fold, suggesting that the circulatory RAS can modulate the
ocular RAS.20 In ocular tissues, Ang-II modulates the ocular
physiology either from local production or systemic circula-
tion. Ang-II is produced by classical enzyme ACE and also
catalyzed by ACE-independent pathways, e.g. via chymase,52
which is also expressed in the eye.33 In addition, recently
angiotensin converting enzyme type 2 (ACE2) is also found in
the eye,25,26,42 which can catalyze Ang-I to Ang (1e9) and
Ang-II to Ang (1e7), which act oppositely to Ang-II.42 Ang
(1e7) mainly acts through novel angiotensin receptor type,
Mas receptor, a G-protein coupled receptor encoded by Mas
proto-oncogene found first in mouse kidney.53 The Mas re-
ceptor acts opposite to AT1R to induce vasodilatation, anti-
proliferation, antifibrosis, and also plays a role in fluid volume
homeostasis.54 Mas receptor is also expressed in ocular tissues
particularly in the retina and ciliary body.50,51
In the eye, Ang-II activates AT1R, a G-protein coupled
receptor which is associated with Gq protein and triggers IP3/
Ca2,55,56 and diacyl glycerol (DAG)/PK-C signaling cas-
cades,57,58 which leads to increase intracellular Ca2þ throughPlease cite this article in press as: Choudhary R, et al., Therapeutic targets of ren
(2016), http://dx.doi.org/10.1016/j.joco.2016.09.009transient release of Ca2þ from endoplasmic reticulum via IP3
receptor and transient receptor potential-V2 (TRPV2) chan-
nels, which is present in the RPE cells.55,56 The Ang-II/AT1R
mediated IP3/DAG signaling cascades further potentiates of
inflammatory/angiogenic molecules in the diseases conditions,
such as vascular endothelial growth factor (VEGF),59e63
extracellular signal-regulated kinase (ERK),64,65 mitogen-
activated protein kinase (MAPK),65 nuclear factor-kappaB
(NF-kB), intracellular adhesion molecule-1 (ICAM-1),66
transforming growth factor-b1 (TGF-b1),67 nicotinamide
adenine dinucleotide phosphate (NADP(H)) oxidase68 and
advanced glycation end products (AGE) accumulation69,70
thus leading to disruption of intracellular signaling and
cellular growth. These findings provide strong evidence that
RAS, especially Ang-II/AT1R signaling, is not just a regulator
of cardio-renal physiology but also regulates an inflammatory
and ocular physiology.
Angiotensin II independent signaling cascades
Apart from AT1R, (P)RR also regulates blood pressure and
cell function, including proliferation, angiogenesis, inflam-
mation, and stimulation of growth factor.71 The (P)RR binds
both with renin and prorenin to exert the catalytic efficiency of
renin and activate (P)RR without conventional proteolysis of
prorenin prosegments,72,73 thus induces signal transduction
pathway that is independent to Ang-II. Renin and prorenin not
only activate the (P)RR but also increase the formation of
Ang-II, through increase in renin activity.67 Moreover, binding
of renin and prorenin also stimulate phosphorylation of (P)RR
on serine and tyrosine residues, which associated with phos-
phorylation of ERK1/2 and an induction of MAPK.73 Huang
et al (2007) reported similar findings that prorenin binds with
(P)RR, induces TGF-b, fibronectin, and collagen via ERK1/
2.74 These findings suggest that inhibition of (P)RR might play
an important role in organ protection that cannot be achieved
with conventional Ang-II blockade. Thus, (P)RR regulates the
organ physiology, including cardiorenal72,75 and ocular
functions.43,76
All of these possible signaling pathways (Fig. 1) play an
important role in the regulation of ocular pathophysiology.
The effects of these signaling cascades of the ocular RAS may
be controlled with RAS inhibitors such as ACEIs, angiotensin
II Type 1 receptor blockers (AT1RBs), and (pro)renin receptor
blockers ((P)RRBs).Ocular disorders and RASThe ocular disorders like DR, AMD, glaucoma, and cata-
ract are leading causes of blindness worldwide.77 All of these
blinding disorders (except cataract) occur in the retina, which
consists of neurons, glia, pigment epithelium and blood ves-
sels. These ocular disorders are associated with the local or
systemic neuronal and vascular homeostasis.12 The findings of
the ocular RAS in retinal cells imply various physiological
functions within the eyes and associated with those blinding
disorders. In the eye, Ang-II has an important role in the
ocular pathophysiology; the above discussions illustrates thatin-angiotensin system in ocular disorders, Journal of Current Ophthalmology
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Table 2
RAS signaling pathways in ocular disorders.
Diseases RAS Signaling pathway Species RAS modulators References
Diabetic retinopathy AT1R and (P)RR signaling potentiate
angiogenic and
inflammatory action in the eye.
Human, rat,
mice, bovine
ACEIs protect DR by reducing the
over expression of VEGF in retina.
AT1RBs protect DR by reducing
inflammatory response and
oxidative stress in the eye.
(P)RRB abolishes the angiogenic
action of ERK signaling molecules.
ACE2 protects retinal ganglion cell death.
60e62,66,68,69,91,
92,94,95,98-102
Glaucoma AT1R signaling regulates aqueous
humor formation, secretion,
uveoscleral outflow, and IOP.
Mas receptor signaling
reduces the IOP.
Human, monkey,
rabbit, rat, bovine
ACEIs reduce IOP by reducing
aqueous humor formation and
increasing uveoscleral outflow.
AT1RBs reduce IOP by increasing
uveoscleral outflow.
Ang (1e7) reduces IOP via Mas
receptor signaling pathway.
ACE2 activation reduces IOP.
49,102,108e116,119
Age-related macular
degeneration
AT1R and (P)RR signaling
potentiate macular
degeneration in the eye.
Human, rat, mice ACEIs, AT1RBs, and (P)RRBs prevent
progression of choroidal neo-vascularization
through suppression of inflammatory response
of RAS signaling.
65,125,128e130
Uveitis AT1R and (P)RR signaling
potentiate ocular inflammation.
Rat, mice AT1RBs and (P)RRBs downregulate the
expression of inflammatory molecules.
ACE2 activation protects
endotoxin-induced uveitis.
43,136e141
Cataract RAS activation potentiates oxidative
stress and ionic imbalance
in the eye lenses.
Rat ACEIs prevent the progression of cataract by
restoring antioxidants defense
system and ionic imbalance.
146e148
ACE2: angiotensin-converting enzyme type 2; ACEIs: angiotensin-converting enzyme inhibitors; Ang (1e7): angiotensin (1e7); AT1R: angiotensin II type 1
receptor; AT1RBs: angiotensin II type 1 receptor blockers; IOP: intra ocular pressure; (P)RR: (pro)renin receptor; (P)RRBs: (pro)renin receptor blockers; RAS:
renin-angiotensin system; VEGF: vascular endothelial growth factor.
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including Muller cells, RPE, blood vessels, and ganglion cells
and are involved in the pathogenesis of those blinding ocular
disorders. The RAS signaling pathways in the particular ocular
diseases are represented in Table 2.
Diabetic retinopathy
Diabetic retinopathy (DR) is one of the most common
microvascular complication of diabetes mellitus.78 Many
factors are involved in the pathogenesis of DR such as meta-
bolic disorders like hyperglycemia, high blood pressure,
hyperlipidemia, age, and oxidative stress.58,79 It is reported
that hyperglycemia induces the inflammatory response,
oxidative stress,12 AGE accumulation,69,70 expression of
growth factors, including VEGF,80,81 TGF-b, pigment
epithelium-derived growth factor,57 insulin-like growth factor-
158 in the eye and finally leads to the development of DR.Fig. 1. Schematic representation of ocular renin-angiotensin system signaling casca
ACE2: angiotensin-converting enzyme type 2; ACEIs: angiotensin-converting enzy
(1e7); Ang (1e9): angiotensin (1e9); Ang-I: angiotensin I; Ang-II: angiotensin II
blockers; AT2R: angiotensin II type 2 receptor; cGMP/NO: cyclic guanosine mon
regulated kinase 1/2; ICAM-1: Intercellular adhesion molecule-1; IP3: inositole-1
ceptor; NFkB: nuclear factor kappa-light-chain-enhancer of activated B cells; PA
pholipase-A2; PL-C: phospholipase-C; (P)RR: (pro)renin receptor; (P)RRBs: (pro)r
endothelial growth factor.
Please cite this article in press as: Choudhary R, et al., Therapeutic targets of ren
(2016), http://dx.doi.org/10.1016/j.joco.2016.09.009Several clinical and experimental research have shown that
RAS plays an important role in the progression of DR,12,59,82
presumably through Ang-II/AT1R mediated actions.
83e85 Ang-
II potentiates VEGF/VEGFR-2 mediated angiogenesis62,81
and increase the permeability of retinal blood vessels, thus,
it may increase the risk of neovascularization86 and hyper-
permeability.87 Ang-II, VEGF,88,89 and prorenin14,90 have
found to be overexpressed in the vitreous humor of prolifer-
ative diabetic retinopathy (PDR) and DR patients. ACEIs have
been shown to produce the protective effect on DR through
reduction of retinal VEGF/VEGFR-2 overexpression in
various preclinical and clinical studies.60,61,91,92 Whereas,
Pradhan et al (2002) found that enalapril, an ACE inhibitor, at
low dose did not significantly reduce the progression of
moderate to severe DR in normotensive Type 2 diabetic pa-
tients,93 suggesting that low dose of ACEIs did not block the
ocular RAS sufficiently enough to exert an effect. Moreover, itdes on the basis of literature.2,12,42,50e76 ACE: angiotensin-converting enzyme;
me inhibitors; AGE: advanced glycation end products; Ang (1e7): angiotensin
; AT1R: angiotensin II type 1 receptor; AT1RBs: angiotensin II type 1 receptor
o phosphate/nitric oxide; DAG: diacyl glycerol; ERK1/2: extracellular signal
,4,5-triphosphate; MAPK: mitogen-activated protein kinase; Mas R: Mas re-
I-1: plasminogen activator inhibitor-1; PK-C: protein kinase-C; PLA2: phos-
enin receptor blockers; TGF-b: transforming growth factor- b; VEGF: vascular
in-angiotensin system in ocular disorders, Journal of Current Ophthalmology
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induced inflammatory response and oxidative stress in the
eye such as VEGF,62,66,94 AGE,94 NF-kB, ICAM-1,66
NADP(H) oxidase68,95 and enhance the neuroprotective
markers, including brain-derived neurotrophic factor, ciliary
neurotrophic factor, tyrosine hydroxylase, glutathione and
caspase activity.68 Furthermore, Miller et al found that
AT1RBs also restore the Ang-II mediated downregulation of
glyoxalase-I in retinal vascular cells, which is a key regulator
of AGE formation.69
Although these multiple events indicate that blockade of
AT1R may have beneficial effects on DR, the Diabetic Reti-
nopathy Candesartan Trials (DIRECT) failed to show a
beneficial effect of Candesartan on retinopathy progression in
the type 1 diabetes patients.96 Failure of the DIRECT pro-
gramme suggested that the pathogenesis of DR also inde-
pendent from Ang-II/AT1R signaling. This hypothesis is
supported by the biological action of a novel receptor (P)RR, a
part of the RAS signaling, which is present in retinal Muller
cells,43 which is a site of VEGF synthesis and its tyrosine
kinase receptors,97 indicating an independent role in the
pathogenesis of DR. Further studies provide the evidence that
(P)RR triggers the expression of angiogenic molecules,
including VEGF/VEGFR2, ERK1/2 and TGFb1 in the retinal
cells and leads to DR, which was abolished by (P)RR/ERK
signaling blockade.98e101 Recently Foureaux et al found that
the activation of ACE2 reduced the death of retinal ganglion
cells in hyperglycemic rats.102 The overall findings suggest
that the RAS is strongly involved in the pathogenesis of DR
and inhibition of these RAS signaling events may have a
beneficial effects on the reduction and prevention of DR and
improves aspects of vascular and neuroglial injury in diabetic
retina.
Glaucoma
Glaucoma, is the multifactorial long-term ocular neuropa-
thy, is generally associated with a progressive loss of retinal
nerve fibers and visual field.103 It is characterized by elevated
intraocular pressure (IOP) and long-term ocular neuropathy,
which is associated with several risk factors, including sys-
temic hypertension, vascular dysfunction, and diabetes.104e107
The most important pathophysiological feature of the diseases
is neurodegeneration of retinal ganglion cells that leads to
increasing IOP. Most of the RAS components including ACE,
Ang-II, and AT1R are present in retinal ganglion cells and
ciliary body, which regulate IOP in the eye. It is known that
ciliary body secrete aqueous humor. Cullinane et al found that
the RAS components in cultured human non-pigmented
ciliary epithelial cells are particularly responsible for
aqueous humor formation and secretion.108 It is reported that
Ang-II induces cell proliferation in bovine trabecular mesh-
work cells,109 which is involved in aqueous humor outflow
and diminishes uveoscleral out-flow.110 These findings indi-
cate that the ocular RAS may implicate in the formation of
aqueous humor, its drainage and regulation of IOP. Therefore,
several researchers showed that inhibition of RAS through
ACE inhibition111,112 and AT1R blockade
113,114 havePlease cite this article in press as: Choudhary R, et al., Therapeutic targets of ren
(2016), http://dx.doi.org/10.1016/j.joco.2016.09.009beneficial effects in both normotensive and glaucomatous
eyes. ACEIs trigger the synthesis of prostaglandins by pre-
venting the breakdown of bradykinin, which leads to lowering
of IOP by increasing uveoscleral outflow.115 Additionally, it
also reduces aqueous humor formation by reducing blood flow
in the ciliary body.116 AT1RBs may be slightly increased
uveoscleral outflow114 and effectively suppresses retinal gan-
glion cell death.117,118
Moreover, the Mas receptor50 and ACE226 are also
expressed in the ocular tissues, which may also regulate the
ocular physiology. Thereby, Mas receptor activator, Ang
(1e7),49 and ACE2 activator, diminazene aceturate
(DIZE)102,119 showed beneficial effects for glaucoma man-
agement via a decrease in IOP. These findings indicate that
RAS inhibition may be effective for treatment of glaucoma.
Age-related macular degeneration
The World Health Organization reported that AMD is
responsible for 8.7% of blindness worldwide.76 Generally, it is
characterized by choroidal neovascularization (CNV; wet
AMD), and atrophy of RPE and photoreceptor cells (dry
AMD).12 Wet AMD is developed through ocular inflamma-
tion, infiltration of macrophages, and AGE formation, and the
main mediator is VEGF.120e122 At present, wet AMD is
treated with the VEGF inhibitors.123,124 The presence of RAS
components in the ocular tissues including RPE, choroid, and
photoreceptor cells and its inflammatory response, suggesting
that deregulation of RAS may enhance the risk of
AMD.125e127 The activation of AT1R and (P)RR in the eye,
potentiate the ERK1/2, VEGF, ICAM-1, and monocyte che-
moattractant protein-1expression in the ocular tissues and
leads to DR and AMD.128,129 Therefore, AT1RBs,
65,130
ACEIs,125 and (P)RRBs129 prevent progression of CNV
through suppression of such inflammatory molecules. These
findings suggested that the controlling of RAS may provide a
pivotal strategy to reduce the progression of wet AMD. At
present, effective therapies are not available for dry AMD, but
nutritional supplements may slow the progression of the dis-
ease.131 Alcazar et al showed (P)RR is involved in the pa-
thology of dry AMD, suggesting that in the future, RAS may
play an important role to manage dry AMD.132
Uveitis
Hyperactivation of RAS involved in the overexpression of
the inflammatory response and immune function. It stimu-
lates accumulation of neutrophils,133 differentiation of den-
dritic cells134 and production of inflammatory chemokines by
vascular endothelial cells.135 Endotoxin-induced uveitis43,136
and experimental autoimmune uveoretinitis137 models upre-
gulate expression of proinflammatory and adhesion molecules
like ICAM-1, interferon-g and interleukin-6. These mole-
cules inhibited by AT1RBs
136e140 and (P)RRBs.43 Recently,
Qiu et al reported that activation of endogenous ACE2 by
DIZE showed the preventive effects on endotoxin-induced
uveitis mouse model.141 All these findings support that the
regulation of RAS may play a beneficial role in the treatment
of uveitis.in-angiotensin system in ocular disorders, Journal of Current Ophthalmology
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Cataractous opacification of the lens is one of leading
causes of visual dysfunction and contributes to 50% of
blindness worldwide.142 Progression of cataract depends on
several risk factors such as diabetes and systemic hyperten-
sion.143 At present, there is no evidence to find the presence of
RAS components in eye lenses, but hyperactivation of RAS
through diabetes and systemic hypertension64,144,145 can
modulate the production of AGE,69,70 reactive oxygen spe-
cies,57 and electrolyte homeostasis,114 which might be
responsible for the increase in the incidence of cataract for-
mation. Moreover, we previously reported that RAS activation
via two-kidney, one clip model significantly modulates the
oxidative stress and ionic imbalance in eye lenses and further
leads to the development of cataract in the hypertensive state,
which is prevented by administration of angiotensin convert-
ing enzyme inhibitor (ramipril).146 Additionally, several re-
searchers found that ACE inhibition showed beneficial effects
in reduction of the cataract through the restoration of the ionic
balance (Naþ/Kþ), free radical scavenging activity, enhanced
the enzymatic and non-enzymatic defense mechanism as well
as inhibition of AGE production.147,148 Therefore, it may be
hypothesized that the ocular RAS has an important role to play
in regulation of lenticular physiology and blockade of Ang-II
mediated action through ACEIs and AT1RBs may reduce the
progression of cataract particularly in diabetes and hyperten-
sive conditions.
Conclusion
The classical RAS are known as blood pressure as well as
electrolyte homeostasis regulator. Recently, it has been
recognized as a proinflammatory mediator and involved in the
various age-related ocular disorders through exacerbation of
the inflammatory molecules. The findings of the RAS com-
ponents in the eye initiate a new therapeutic approach to
attenuate the ocular disorders through RAS inhibitors such as
ACEIs and AT1RBs. The new RAS modulators like renin in-
hibitors, (P)RRBs, AT2R, Mas receptor have shown potential
role in the circulatory as well as local RAS modulation and
had beneficial effects on the management of cardio-renal and
ocular disorders. The present review describes the ocular RAS
in the pathophysiology of such ocular disorders and effects of
classical and newer RAS inhibitors in respect of pathogenic
inflammatory molecules that elicit the newer approach in
ophthalmic research. In future novel RAS components like
Ang-III, Ang-IV, and its receptor AT4R may also have an
important ocular physiology. Therefore, the work to develop
the novel and selective RAS inhibitors may hold great promise
to attenuate ocular disorders and help to treat life-threatening
blinding disorders.
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